PRC
ALXN

Pearl River Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Pearl River Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,683
Closed -$506K – 776
2019
Q4 		$506K Buy
+4,683
New +$501K 0.19% 192
2019
Q1 		– Sell
-1,295
Closed -$126K – 927
2018
Q4 		$126K Buy
+1,295
New +$153K 0.58% 22

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pearl River Capital's ALXN Position: Q1 2020 in Review

Pearl River Capital sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 4,683 shares — an estimated $506K sold.

Pearl River Capital first reported a position in ALXN in Q4 2018 and held it in 2 quarters. The position peaked at $506K in Q4 2019. 653 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Pearl River Capital reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Pearl River Capital sold 4,683 Alexion Pharmaceuticals shares in Q1 2020, an estimated $506K.
  • Pearl River Capital first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Pearl River Capital's Alexion Pharmaceuticals position peaked at $506K in Q4 2019.
  • 653 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Pearl River Capital's 13F filing for Q1 2020, filed 6 May 2020.